Literature DB >> 18670800

Frequency of nocturnal sudden death in patients with multiple system atrophy.

T Shimohata1, T Ozawa, H Nakayama, M Tomita, H Shinoda, M Nishizawa.   

Abstract

Sudden death has been reported in patients with multiple system atrophy (MSA), although the frequency of this event has not been well delineated. We investigated the frequency and potential causes of sudden death in patients with MSA. During the 5-year observation period, 10 of 45 patients with probable MSA died. The causes of death included sudden death of unknown etiology (seven patients), aspiration pneumonia (one patient), asphyxia after vomiting (one patient), and lung cancer (one patient). The mean survival time of patients with sudden death was 63.0 +/- 24.7 months (range, 39-116 months). Among seven patients who experienced sudden death, six were found to have died during sleep. Among these patients, two had been treated with tracheostomy and three with continuous positive airway pressure (CPAP) or noninvasive positive pressure ventilation (NPPV) during sleep, suggesting that these treatments do not always prevent sudden death in patients with MSA. Nocturnal sudden death should be recognized as the most common mechanism of death in patients with MSA.

Entities:  

Mesh:

Year:  2008        PMID: 18670800     DOI: 10.1007/s00415-008-0941-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

Review 1.  Consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; P A Low; N Quinn; A Albanese; Y Ben-Shlomo; C J Fowler; H Kaufmann; T Klockgether; A E Lang; P L Lantos; I Litvan; C J Mathias; E Oliver; D Robertson; I Schatz; G K Wenning
Journal:  J Neurol Sci       Date:  1999-02-01       Impact factor: 3.181

2.  Impaired chemosensitivity to hypoxia is a marker of multiple system atrophy.

Authors:  Takehide Tsuda; Hiroshi Onodera; Shinichi Okabe; Yoshihiro Kikuchi; Yasuto Itoyama
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

3.  Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy.

Authors:  A Iranzo; J Santamaria; E Tolosa; I Vilaseca; F Valldeoriola; M J Martí; E Muñoz
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

4.  Causes of death in multiple system atrophy.

Authors:  Spiridon Papapetropoulos; Alexander Tuchman; Daniel Laufer; Athanassios G Papatsoris; Nektarios Papapetropoulos; Deborah C Mash
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03       Impact factor: 10.154

5.  Early diagnosis and stage classification of vocal cord abductor paralysis in patients with multiple system atrophy.

Authors:  E Isozaki; A Naito; S Horiguchi; R Kawamura; T Hayashida; H Tanabe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

6.  Stridor and death in multiple system atrophy.

Authors:  M H Silber; S Levine
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

7.  Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy.

Authors:  K Jin; S Okabe; K Chida; N Abe; T Kimpara; A Ohnuma; H Nomura; Y Itoyama; H Onodera
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

8.  Olivopontocerebellar atrophy with velopharyngolaryngeal paralysis: a contribution to the somatotopy of the nucleus ambiguus.

Authors:  J Lapresle; A Annabi
Journal:  J Neuropathol Exp Neurol       Date:  1979-07       Impact factor: 3.685

9.  Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure.

Authors:  F E Munschauer; L Loh; R Bannister; J Newsom-Davis
Journal:  Neurology       Date:  1990-04       Impact factor: 9.910

10.  Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy.

Authors:  M Konagaya; Y Konagaya; M Iida
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-12       Impact factor: 10.154

View more
  26 in total

1.  Posterior Reversible Encephalopathy Syndrome in a Patient With Multiple System Atrophy.

Authors:  Sarah Debray; Saartje Van de Vondel; Thomas Tousseyn; Dietmar Rudolf Thal; Maarten Dewil
Journal:  Mov Disord Clin Pract       Date:  2017-05-25

Review 2.  How does homeostasis happen? Integrative physiological, systems biological, and evolutionary perspectives.

Authors:  David S Goldstein
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-01-16       Impact factor: 3.619

3.  An exceptional case of MSA-P.

Authors:  Thomas Foki; Suna Steininger; Gregor Kasprian; Gregor K Wenning; Elisabeth Fertl; Walter Pirker
Journal:  J Neurol       Date:  2013-02-23       Impact factor: 4.849

4.  Sleep Disorders in Atypical Parkinsonism.

Authors:  Sabra M Abbott; Aleksandar Videnovic
Journal:  Mov Disord Clin Pract       Date:  2014-06-01

Review 5.  Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders.

Authors:  Lisa Klingelhoefer; Elisaveta Sokolov; K Ray Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2014-04-03       Impact factor: 3.575

Review 6.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 7.  Sleep-disordered breathing in neurodegenerative diseases.

Authors:  Carles Gaig; Alex Iranzo
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

8.  Central hypoventilation in progressive supranuclear palsy.

Authors:  Kory S Herrick; Randy Woltjer; Thao Pham; Megan Chalupsky; Amie L Hiller
Journal:  Mov Disord Clin Pract       Date:  2016-05-19

9.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

10.  Sleep dysfunction in multiple system atrophy.

Authors:  Luigi Ferini-Strambi; Sara Marelli
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.